Focus on potential best-in-class products
providing whole solution for coronavirus pandemic
Nasal Vaccine for Covid-19
Easy to Administer
Potential for Immunity in Elderly and Immunocompromised
Drawing on prior experience developing successful vaccine formulation candidates for a lethal coronavirus (MERS), a team that has taken vaccines and therapeutics to market, Vaxcine has devised a novel nasal vaccine for Covid-19 that could generate greater immunity where it is needed than injectable approaches, be more convenient to use, be easier to distribute globally, and impose a lower burden on healthcare systems (self-administration potential).
Potential best-in-class through double-action using unique multi-array, antigen-presenting and Th2 cell mimetic, delivered via the nose.
Advantages
Easy to administer, nasal |
Avoiding injections, more patient-friendly |
Generating immunity where needed |
Stopping virus at sites of entry eg lung, nose |
Self-administration potential |
Reducing health care administration costs |
Rapid, world-wide roll-out potential |
Simplified logistics/distribution and greater access for patients |
No needles hazardous waste |
No need for disposing needles |
Potential for immunity in elderly and immunocompromised patients |
Overcomes need for T-cell help |
Rapid incorporation of new antigens |
New antigens can be incorporated rapidly to keep up with viral mutations |
Simplified clinical development |
All formulation excipients are GRAS/Pharmacopoeia-listed |
Oral Vaccine Against Covid-19
Easy to Administer and Distribute
Potential Strong IgA and IgG Immunity in Mucosal Surfaces
Vaxcine has devised an oral vaccine for the Covid-19 virus to generate greater immunity than injectable approaches for the important mucosal surfaces, be more convenient to take (oral, easy-to-swallow), easier to distribute globally and a lower burden to healthcare systems (with self-administration potential). This development draws upon prior experience developing successful vaccine formulation candidates for a lethal coronavirus (MERS) in collaboration with the UK Defence Science and Technology Laboratory (DSTL) among other institutions and a team that has taken vaccines and therapeutics to market.
Advantages
Oral, Easy-to-swallow, administer |
Avoiding injections, easier for elderly, children |
Generating immunity where needed |
Stopping virus in throat & lung |
Self-administration potential |
Reducing health care administration costs |
Rapid, world-wide roll-out potential |
Non-refrigeration, simplified logisitics/distribution and greater access for all |
No hazardous waste |
No need for disposing needles etc |
Lower Toxicity Risk: Simplified clinical development |
All formulation excipients are low risk GRAS/Pharmacopoeia listed |